Anti-Candida albicans of Probiotic

Abstract

Candida albicans is the most common opportunistic pathogen. Which causes candidiasis infection, commoning found in patients with viral infection human immunodeficiency virus (HIV), Acquired immunodeficiency syndrome (AID_S), patients receiving medication antibiotic, patients who underwent surgery and patients undergoing chemotherapy. These patients may experience oral infections that may spread into the blood stream affecting the functioning of the brain, bones and respiratory system. In addition, C. albicans also have resistance to antifungal drugs. Which makes it difficult to treat infections from C. albicans. However, the best way to control resistance is to choose the appropriate antimicrobial drug. Including finding new ways to treat infectious diseases such as the use of probiotics to inhibit pathogenic microorganisms. We collect the efficacy of probiotics on inhibition of growth and biofilm formation of C. albicans in vitro and in vivo. To be a guideline for the study, research and development of bioactive compounds to replace the use of synthetic chemicals or further development into probiotic products for the prevention and treatment of Candida in the future.